Revenue: As of FY2025, the actual value is USD 9.467 B, beating the estimate of USD 9.441 B.EPS: As of FY2025, the actual value is USD 6.02, beating the estimate of USD 5.995.EBIT: As of FY2025, the actual value is USD 3.675 B.<h4>Segment Revenue</h4><ul><li>Total Revenue: 硕腾 (Zoetis Inc.) reported total revenue of $9,467 million in 2025, a 2% increase from $9,256 million in 2024, which itself was an 8% increase from $8,544 million in 2023. Operational revenue growth for 2025 was 3%, with foreign exchange unfavorably impacting reported revenue growth by -1%.</li><li>United States Segment: Revenue for the U.S. segment was $5,097 million in 2025, representing 54% of total revenue, remaining relatively flat compared to $5,074 million in 2024. Within this segment, companion animal revenue was $4,220 million, showing 4% operational growth, while livestock revenue was $877 million, declining by -14% operationally in 2025 compared to 2024.</li><li>International Segment: Revenue for the International segment was $4,254 million in 2025, comprising 45% of total revenue, an increase of 4% from $4,102 million in 2024. Operational revenue growth was 5%, while foreign exchange unfavorably impacted revenue by -1%. Companion animal revenue was $2,367 million with 7% operational growth, and livestock revenue was $1,887 million with 2% operational growth in 2025 compared to 2024.</li><li>Contract Manufacturing &amp; Human Health: Revenue from this segment was $116 million in 2025, approximately 1% of total revenue, marking a 45% increase from $80 million in 2024.</li></ul><h4>Revenue by Species (Global)</h4><ul><li>Companion animal products: Contributed $6,587 million (70% of total revenue) in 2025, a 5% increase from $6,278 million in 2024.</li><li>Livestock products: Contributed $2,764 million (29% of total revenue) in 2025, a -5% decrease from $2,898 million in 2024.</li></ul><h4>Unique Metrics - Top-Selling Products (2025)</h4><ul><li>Simparica/Simparica Trio and Apoquel/Apoquel Chewable were the top two product lines, contributing approximately 16% and 12% of total revenue, respectively.</li><li>The top five product lines, including Cytopoint, Librela, and ceftiofur line, contributed approximately 42% of total revenue, while the top ten product lines accounted for about 57% of total revenue.</li><li>Products representing approximately 1% or more of revenue collectively comprised around 71% of total revenue, and revenue attributable to antibacterials for livestock was approximately $713 million in 2025.</li></ul><h4>Operational Costs</h4><ul><li>Cost of sales: $2,666 million (28.2% of revenue) in 2025, a -2% decrease from $2,719 million (29.4% of revenue) in 2024.</li><li>Selling, general and administrative expenses: $2,378 million (25% of revenue) in 2025, a 3% increase from $2,318 million (25% of revenue) in 2024.</li><li>Research and development expenses: $698 million (7% of revenue) in 2025, a 2% increase from $686 million (7% of revenue) in 2024.</li><li>Amortization of intangible assets: $128 million in 2025, a -9% decrease from $141 million in 2024.</li><li>Restructuring charges and certain acquisition and divestiture-related costs: $51 million in 2025, a -4% decrease from $53 million in 2024.</li><li>Interest expense, net of capitalized interest: $222 million in 2025, a -1% decrease from $225 million in 2024.</li><li>Other (income)/deductions—net: - $36 million in 2025, compared to - $19 million in 2024.</li></ul><h4>Cash Flow</h4><ul><li>Net cash provided by operating activities: $2,904 million in 2025, a decrease from $2,953 million in 2024.</li><li>Net cash used in investing activities: - $748 million in 2025, an increase from - $315 million in 2024.</li><li>Net cash used in financing activities: - $1,870 million in 2025, a decrease from - $2,660 million in 2024.</li></ul><h4>Outlook / Guidance</h4>硕腾 (Zoetis Inc.) plans to eliminate the one-month reporting lag for its International Subsidiaries in 2026 to align their fiscal year-end to December 31 for seamless financial consolidation. The company anticipates that the sales acceleration observed in the International segment during Q4 2025 due to this alignment will not recur at the end of fiscal year 2026. This alignment process also involves changes in the timing of annual price increases and delayed processing of some December 2025 customer orders into 2026.

Zoetis | 10-K: FY2025 Revenue Beats Estimate at USD 9.467 B